UTEST graduate Whirlscape was featured in Raju Mudhar's Toronto Star article, "Toronto’s Whirlscape debuts tiny Minuum keyboard on iPhone," which examines the company's successful launch of their innovative, one-line keyboard for Apple's iOS 8.
The UTEST program, co-directed by MaRS Innovation and the University of Toronto's Innovations & Partnerships Office, gives nascent software companies start-up funding, office space, mentoring and business strategy support. Whirlscape was among the program's first cohort.
The article was published October 6, 2014. Here's an excerpt:
An Indiegogo success 18 ...
Program's second cohort includes eQOL, E-Twenty Development, Root2Crown, Treata Smart Solutions and TrendMD
TORONTO (May 14, 2013) — Five companies tackling pervasive healthcare challenges — such as assessing dental health, helping patients and medical personnel navigate hospitals with greater ease, staying current with medical literature, or creating digital tools to help care for the elderly or those with chronic health conditions — have been admitted to the University of Toronto Early Stage Technology (UTEST) program’s second cohort.
UTEST, supported by the University of ...
Shotlst is one of six inaugural UTEST companies; next UTEST application round to begin shortly
What if you could turn on Microsoft Word’s “track changes” tool and apply it at will to the world around you?
Sound like science fiction?
Meet Matt Ratto, a professor in the University of T’s Faculty of Information, and Mike Borg, a recent graduate of the faculty. They’ve formed Shotlst, a new software company being incubated by the University of Toronto Early Stage Technology (UTEST) program.
The central metaphor of ...
Funds secured from MaRS Innovation, HTX, OICR and CCR to speed commercialization of Xagenic's rapid molecular diagnostic technology
TORONTO (October 13, 2010) – MaRS Innovation today announced a $500,000 investment in its Toronto-based spin-off company, Xagenic Inc.
When combined with funds from other investors and lenders, the new working capital provided to Xagenic totals $1.04 million.
This follow‐on financing includes a $300,000 loan from HTX, The Health Technology Exchange; $200,000 from the Ontario Institute for Cancer Research; $40,000 from the Ontario Centre of Excellence ...